Nicolas Girard, MD

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).